Retina drug on FDA fast track

Article

NT-501, a Ciliary Neurotrophic Factor (CNTF)-releasing polymer indicated for the treatment of visual loss in retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD), has been granted a Fast Track designation by the FDA, Neurotech Pharmaceuticals Inc, the compound's manufacturer, has announced.

NT-501, a Ciliary Neurotrophic Factor (CNTF)-releasing polymer indicated for the treatment of visual loss in retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD), has been granted a Fast Track designation by the FDA, Neurotech Pharmaceuticals Inc, the compound's manufacturer, has announced.

Neurotech is conducting three studies on NT-501: two Phase II/III trials in RP, for early (n=60) and late (n=60) stage disease; one Phase II trial in advanced dry AMD (n=48). All trials are randomized, multi-centre, double-masked and sham-controlled.

The RP trials are dose-ranging studies, in which subjects receive a dose of NT-501 in one eye and a sham treatment in the other. The primary end-point of the early-stage study is visual field sensitivity; for the late-stage study, best corrected visual acuity. Subjects in the dry AMD trial also receive a dose of NT-501 in one eye and a sham treatment in the other: the primary efficacy endpoint is best corrected visual acuity.

Neurotech plans to announce top-line results of these three studies early next year, as was originally planned; the Fast Track designation, however, will allow the company to accelerate its clinical development programmes.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.